Molecular & Translational Characterisation of IMiD-Mediated BET-Protein Degradation in Multiple Myeloma

分子

• 批准号: nhmrc : 1127387
• 负责人: A/Pr Jake Shortt
• 金额: $ 33.97万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-translational-characterisation-multiple-myeloma/948007
• 关键词: Molecular; Translational; Characterisation; IMiD; Mediated

Thalidomide-like drugs (called IMiDs) are an essential treatment for multiple myeloma, a common incurable blood cancer. We have discovered that IMiDs destroy proteins that myeloma cells use to ‘read’ cancer-causing genes in their own DNA. We will therefore investigate how important the destruction of these ‘gene readers’ is in myeloma cells, including patient samples. This will set up future studies targeting ‘gene readers’ using IMiDs in combination with other targeted drugs in clinical trials.

沙利度胺类药物（称为IMiDs）是多发性骨髓瘤的基本治疗方法，多发性骨髓瘤是一种常见的无法治愈的血癌。我们发现IMiDs破坏了骨髓瘤细胞用来“读取”自身DNA中致癌基因的蛋白质。因此，我们将研究这些“基因解读器”在骨髓瘤细胞（包括患者样本）中的破坏有多重要。这将为在临床试验中使用IMiDs与其他靶向药物联合针对“基因读取器”的未来研究奠定基础。